8-K Announcements
6Material company update
Mar 4, 2026·SEC
Material company update
Nov 6, 2025·SEC
Material company update
Oct 27, 2025·SEC
Impact BioMedical Inc.(IBO)Earnings, Financials & Key Ratios
IBO•AMEX
$0.47
Price updated Jun 27, 2026
AboutImpact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. It provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. The company also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, it develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. The company was incorporated in 2018 and is based in Houston, Texas.Show more
- Revenue$32K-98.6%
- EBITDA-$3M-449.1%
- Net Income-$12M-477.0%
- EPS (Diluted)-0.38-3700.0%
- Gross Margin-1225%-1325.0%
- EBITDA Margin-9765.63%-25531.0%
- Operating Margin-13343.75%-56483.4%
- Net Margin-36993.75%-41932.6%
- ROE-103.88%-266.4%
IBO Price & Volume
Impact BioMedical Inc. (IBO) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Deficit Signals Existential Liquidity Risk
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent insolvency and liquidity
Key Thesis Takeaways
- Impact BioMedical faces an existential threat as its commercial operations have failed to generate meaningful revenue, with quarterly figures frequently hitting zero and TTM revenue totaling only $32,000.
- The company's reliance on intangible assets, which comprise the bulk of its $17.1 million in total assets, masks a severe lack of tangible value and operational scalability.
- Investors should remain cautious as the firm's cash reserves have dwindled to a nominal $3,000, necessitating potentially dilutive capital raises to sustain its speculative biotechnology portfolio.
Verdict Logic
the company's cash reserves have plummeted to a nominal $3,000, leaving it with virtually no liquidity buffer to support its ongoing operations.
IBO Growth Metrics
Impact BioMedical Inc. (IBO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-13.82%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-227.32%
5 Years-12.54%
3 Years-12.88%
Last Year-31.93%
IBO Recent Earnings
Impact BioMedical Inc. (IBO) EPS & revenue vs analyst estimates — last 4 quarters
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.02
—
Rev
$7,000
—
Q2 2026
Mar 27, 2026Metric
Actual
Est
EPS
$0.42
—
Rev
$7,000
—
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$0.12
—
Rev
$18,000
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$1.18
—
Rev
$5,119
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.02 | $7,000 |
| Q2 2026 | Mar 27, 2026 | $0.42 | $7,000 |
| Q4 2025 | Nov 7, 2025 | $0.12 | $18,000 |
| Q3 2025 | Aug 14, 2025 | $1.18 | $5,119 |
Based on last 7 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Impact BioMedical Inc. (IBO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.47 | $50.77M | -1.24 | -98.63% | -36993.75% | -103.88% | — | |
| $1.34 | $23.94M | -2.13 | — | — | -0% | — | |
| $8.88 | $1.46B | 3.50 | 64.69% | -14.73% | — | — | |
| $0.54 | $130.54M | 7.71 | 726.68% | 14.51% | 61.43% | — | |
| $1.50 | $507.78M | -6.52 | 8.83% | -1605.22% | -127987.5% | — | |
| $8.75 | $2.03B | 14.58 | 19.63% | 32.43% | 38.97% | — |
Compare IBO vs Peers
Impact BioMedical Inc. (IBO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IBO SEC Filings & Documents
Impact BioMedical Inc. (IBO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when IBO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IBO Frequently Asked Questions
Impact BioMedical Inc. (IBO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Impact BioMedical Inc.'s revenue?
Impact BioMedical Inc. (IBO) reported $0.0M in revenue for fiscal year 2025.
How fast is Impact BioMedical Inc. growing?
Impact BioMedical Inc. (IBO) saw revenue decline by 98.6% over the past year.
Is IBO profitable?
Impact BioMedical Inc. (IBO) reported a net loss of $12.9M for fiscal year 2025.
Dividend & Returns
What is IBO's return on equity?
Impact BioMedical Inc. (IBO) has a return on equity (ROE) of -103.9%. Negative ROE indicates the company is unprofitable.
What is Impact BioMedical Inc.'s free cash flow?
Impact BioMedical Inc. (IBO) had negative free cash flow of $1.7M in fiscal year 2025, likely due to heavy capital investments.